**Core tip:** From 2014 on the second wave of direct acting antiviral agents was available for treatment of chronic hepatitis C infection. Due to the more heterogeneous character of patients in the "real world", the therapeutic performance of these new drugs outside randomized clinical trials is of interest. Therefore, in this monocentric retrospective cohort study, we analyzed the efficacy, safety, and predictors of sustained virological response 12 for treatment with combinations of second generation direct acting antivirals in a "real-world" setting.

INTRODUCTION
============

Chronic infection with Hepatitis C virus (HCV) is still one of the main causes for liver disease with a prevalence of 0.2%-2% in Western countries, while worldwide about 80 million people are threatened by HCV\[[@B1]-[@B4]\]. After many years of just moderate sustained viral response (SVR) rates of around 50%-60% through all genotypes (GT) under Interferon (IFN)-based treatment regimens\[[@B5]-[@B9]\], in 2011 the first direct acting antiviral compounds (DAA), the protease inhibitors (PI) Telaprevir and Boceprevir had been approved for treatment of HCV GT1\[[@B10]-[@B14]\]. Beyond that, promising SVR results obtained in the clinical trials were shown to be achieved also in "real-world" settings\[[@B15],[@B16]\]. However, treatment with first generation DAA was only subject to GT1 patients, and antiviral potency was counteracted by aggravated side-effects. For the second wave of DAA, diverse drug classes were developed: (1) polymerase-; (2) NS5A-, as well as (3) new protease inhibitors (PI). From early 2014 on, consecutively the first-in-class polymerase inhibitor Sofosbuvir (SOF), a second wave PI Simeprevir (SMV), the first-in-class NS5A inhibitor Daclatasvir (DCV), and another NS5A inhibitor Ledipasvir (LDV), were approved. Accordingly, for the first time, IFN-free treatments consisting of combinations of these DAA, with or without Ribavirin (R), were possible, showing impressive SVR rates and a superior side effect profile. From 2014 until 2015, SOF constituted the "backbone" of most combination treatments: in combination with R alone (SOF/R), with pegylated Interferon and R (SOF/PR), or combined with SMV (SOF/SMV), DCV (SOF/DCV), or LDV (SOF/LDV) with or without R. In 2015, this "monopoly" was tackled by the fixed combination of Dasabuvir, a non-nucleosidic polymerase inhibitor, with Ombitasvir, and Paritaprevir/r (3D).

Now, after more than two years since the approval of SOF and its combination partners, and a year after approval of the 3D regimen, we here summarize our experiences with these combination treatments being obtained in the "real-world" setting of a tertiary center. This retrospective analysis was conducted to gather data on the antiviral efficacy and safety of second generation DAA treatment with respect to sustained virological response 12 wk after conclusion of treatment (SVR12), and to determine predictors of SVR12 in this setting.

MATERIALS AND METHODS
=====================

The clinical characteristics of our retrospective cohort are presented in Table [1](#T1){ref-type="table"}. The study cohort includes all 260 consecutive patients, who were treated at our center with a DAA containing therapy between January 2014 and December 2015. Treatment decisions were based on antiviral activity against GT of respective DAA according to approval, severity of liver disease, comorbidities, approval of DAA at time-point of treatment start, and economic reasons.

###### 

Characteristics of study cohort patients

  **Demographics**                                                                                         
  -------------------------------------------------------- ----------------------------------------------- ------------------------------
  *n*                                                                                                      260
  Age                                                      (yr)[1](#T1FN1){ref-type="table-fn"}            53 (44-60)
  Sex                                                      Male/Female *n* (%)                             157 (60)/103 (40)
  Baseline viral characteristics                                                                           
  Genotype 1a/1b/1x                                        *n* (%)/*n* (%)/*n* (%)                         76 (29)/115 (44)/3(1)
  Genotype 2/3                                             *n* (%)/*n* (%)                                 8 (3)/44 (17)
  Genotype 4/5/6                                           *n* (%)/*n* (%)                                 11 (4)/1 (0.4)/2 (0.8)
  Baseline viral load                                      (IU/mL)[1](#T1FN1){ref-type="table-fn"}         1.33 Mio. (414.750-3.4 Mio.)
  Baseline viral load ≥ 800.000 IU/mL                      *n* (%)                                         169 (65)
  Baseline viral load ≥ 6 Mio IU/mL                        *n* (%)                                         28 (11)
  Special populations                                                                                      
  LCi[2](#T1FN2){ref-type="table-fn"}                      *n* (%)                                         89 (34)
  Low platelets (≤ 100/nL)                                 *n* (%)                                         56 (22)
  Post Liver Transplantation                               *n* (%)                                         17 (7)
  Patients ≥ 60 yr                                         *n* (%)                                         72 (28)
  Patients with MELD score ≥ 10                            *n* (%)                                         25 (10)
  Treatment history                                                                                        
  Treatment experienced                                    *n* (%)                                         144 (55)
  Treatment regimens \[thereof liver cirrhosis *n* (%)\]                                                   
  SOF PR                                                   *n* (%)/LCi *n* (%)                             51 (20)/6 (12)
  SOF R                                                    *n* (%)/LCi *n* (%)                             10 (4)/4 (40)
  SOF SMV                                                  *n* (%)/LCi *n* (%)/R *n* (%)                   30 (12)/16 (53)/15 (19)
  SOF DCV                                                  *n* (%)/LCi *n* (%)/R *n* (%)                   81 (31)/42 (52)/12 (40)
  SOF LDV                                                  *n* (%)/LCi *n* (%)/R *n* (%)                   73 (28)/17 (23)/16 (22)
  3D                                                       *n* (%)/LCi *n* (%)/R *n* (%)                   15 (6)/4 (27)/6 (40)
  Baseline clinical chemistry                                                                              
  WBC                                                      (/μL)[1](#T1FN1){ref-type="table-fn"}           5935 (4683-7670)
  Hemoglobin                                               (g/dL)[1](#T1FN1){ref-type="table-fn"}          14.5 (13.1-15.6)
  Platelets                                                (thousand/μL)[1](#T1FN1){ref-type="table-fn"}   174 (113-228)
  Creatinine                                               (mg/dL)[1](#T1FN1){ref-type="table-fn"}         0.7 (0.6-0.8)
  Total Bilirubin                                          (mg/dL)[1](#T1FN1){ref-type="table-fn"}         0.7 (0.5-1.0)
  INR                                                      INR[1](#T1FN1){ref-type="table-fn"}             1 (1-1)
  ALT                                                      IU/l[1](#T1FN1){ref-type="table-fn"}            67 (44-105)

Data are presented as medians (interquartile ranges in parentheses);

By liver histology, Fibroscan (\> 12.5 kPa), or by clinical diagnosis (*e.g*., esophageal varices, ascites, distinct ultrasound signs of portal hypertension or liver cirrhosis). 1x: Genotype 1, no subtype differentiable; LCi: Liver cirrhosis; MELD: Model of end stage liver disease; P: Pegylated Interferon; R: Ribavirin; SOF: Sofosbuvir; SMV: Simeprevir; LDV: Ledipasvir; DCV: Daclatasvir; 3D: Dasabuvir, Ombitasvir, and Paritaprevir/r; WBC: White blood cell count; INR: International normalized ratio; ALT: Alanine-aminotransferase.

If possible, IFN-free treatments were favored. Treatment of patients presenting hepatic impairment was postponed, if possible, until IFN-free regimens were available. 17 patients were treated in the context of post-liver transplantation, two of these with cholestatic recurrence of HCV after liver transplantation who were treated with SOF/DCV in a compassionate use program. Following the dates of approval of the different DAA, patients were treated with SOF/R or SOF/PR respectively, when being started with treatment in early 2014, until later on additionally a SOF/SMV combination became available. From autumn 2014 on, patients were, if possible, treated with SOF/DCV, and again later on this year, patients could be treated also with SOF/LDV. From Early 2015 on, patients could also be treated with the 3D regimen. Proportions of different treatment regimens are shown in Table [1](#T1){ref-type="table"}.

Baseline clinical chemistry is shown in Table [1](#T1){ref-type="table"}. 13/260 patients had leukopenia (leukocyte count \< 3000/μL), 56/260 patients presented with thrombopenia (platelet count \< 100/nL). Transaminases were elevated in 223/260 patients (ALT \> 35 IU/mL). Data of albumin levels were available only on an occasional basis.

Diagnosis of liver cirrhosis was based upon liver histology, Fibroscan (\> 12.5 kPa), or clinical diagnosis (*e.g*., ascites, esophageal varices, distinct sonographic signs of portal hypertension or liver cirrhosis). For assessment of severity of liver disease, we calculated the MELD score. In this retrospective analysis, Child Turcotte Pugh score or other assessment scores for severity of liver disease could not be calculated due to lack of data\[[@B17],[@B18]\]. For retrospective identification of patients with possible portal hypertension, a threshold of 100 platelets/nL was assumed.

For virological analyses Roche CobasAmpliprep/Roche CobasTaqMan \[Roche Diagnostics GmbH, Mannheim, Germany; lower limit of quantification (LLOQ) 15 IU/mL\] was used.

The institutional review board of the Medical Faculty of the University of Tübingen approved this retrospective analysis and waived the need for written informed consent because of the anonymous evaluation of patient data from patient records.

Data were statistically analyzed using Microsoft Office Excel, SPSS, and Graph Pad Prism. 4/260 patients were lost to follow-up. These patients were excluded from analysis \[modified intention to treat analysis (mITT)\].

RESULTS
=======

Analysis of SVR12 rates
-----------------------

The overall SVR12 rate is shown in Figure [1](#F1){ref-type="fig"} (93.7%; 240/256 patients mITT; of those, 2/256 patients discontinued treatment prematurely, but achieved SVR 12; 4/260 patients were lost to follow-up and were excluded from analysis. SVR12 rates according to GT, and diverse treatment regimens are shown in Figure [2](#F2){ref-type="fig"}. Additionally, SVR12 rates according to several baseline characteristics (sex, age, cirrhosis status, platelet count, MELD score, viral load, and treatment experienced patients) and early viral kinetics are shown in Table [2](#T2){ref-type="table"}. SVR12 rates in different GT (1a, 1b, 2, 3, 4, and 6) ranged from 90%-100%. One additional patient with HCV GT 5 achieved SVR 12. Depending on different treatment regimens, SVR12 rates ranged from 92%-100%. Special subgroups of patients known to be "hard-to-treat" (patients post-liver transplantation (*n* = 17)\], patients with liver cirrhosis (*n* = 89), patients of older age (≥ 60 years; *n* = 72), and treatment experienced patients (*n* = 144) achieved highly acceptable SVR12 rates in the range of 88%-95%. However, patients with low platelet count at baseline (\< 100/nL; *n* = 56), and patients with a MELD score ≥ 10 at baseline (*n* = 25) achieved SVR12 rates of 82%, and 72%, respectively.

![Overall treatment outcome. ^1^Two hundred and sixty consecutive patients were treated with second generation direct acting antiviral (DAA) combinations; 14/260 patients lost to follow-up were not included in our analysis \[modified intention-to-treat (mITT) analysis\]. Additionally, 2 patients discontinued treatment prematurely, but achieved sustained virological response (SVR); accordingly these 2 patients also were counted as SVR12 patients.](WJG-22-8050-g001){#F1}

###### 

Predictive model of sustained virological response analyzed for all patients treated with second generation direct acting antiviracombination therapy (*n* = 256)

                                             **SVR 12 (n/N; %)[2](#T2FN2){ref-type="table-fn"}**   **Univariate analysis**   **Multivariate analysis**                          
  ------------------------------------------ ----------------------------------------------------- ------------------------- --------------------------- ---------------------- -----------
  Viral kinetics                                                                                                                                                                
  RVR                                        143/152; 94%                                                                                                                       
  *vs* Non-RVR                               83/89; 93%                                            1.149 (0.395, 3.341)      0.799                       0.728                  
  Baseline demographic parameters                                                                                                                                               
  Fibrosis                                                                                                                                                                      
  Liver Cirrhosis                            76/87; 87%                                                                                                                         
  *vs* no Liver Cirrhosis                    164/169; 97%                                          0.211 (0.071, 0.627)      0.005                       0.290                  
  Transplant Status                                                                                                                                                             
  LTx                                        15/17; 88%                                                                                                                         
  *vs* no LTx                                225/239; 94%                                          0.467 (0.097, 2.246)      0.467                       0.972                  
  Sex                                                                                                                                                                           
  Male                                       140/153; 92%                                                                                                                       
  *vs* female                                100/103; 97%                                          0.329 (0.091, 1.184)      0.089                       0.282                  
  Age                                                                                                                                                                           
  Patients ≥ 60 yr                           68/71; 96%                                                                                                                         
  *vs* \< 60 yr                              172/185; 93%                                          0.999 (0.959, 1.04)       0.948                       0.078                  
  Baseline viral load                                                                                                                                                           
  High viral load (\> 6 Mio IU/mL)           28/28; 100%                                                                                                                        
  *vs* low viral load (≤ 6 Mio IU/mL)        212/228; 93%                                          NA                        0.998                       0.251                  
  Genotype                                                                                                                                                                      
  1                                          180/192; 93%                                                                                                                       
  *vs 3*                                     38/42; 90%                                            1.606 (0.510, 5.060)      0.418                       0.424                  
  Genotype[1](#T2FN1){ref-type="table-fn"}                                                                                                                                      
  1 IFN-free, per protocol                   160/164/; 98%                                                                                                                      
  *vs* 3 IFN-free, per protocol              16/20/; 80%                                           5.000 (1.355, 18.45)      0.016                       NA                     
  Baseline platelet count                                                                                                                                                       
  Platelets ≤ 100/nL                         45/55; 82%                                                                                                                         
  *vs* \> 100/nL                             195/201; 97%                                          0.138 (0.048, 0.401)      \< 0.0001                   0.24 (0.072, 0.88)     0.031
  Baseline MELD ≥ 10                                                                                                                                                            
  MELD ≥ 10                                  18/25; 72%                                                                                                                         
  *vs* MELD \< 10                            222/231; 96%                                          0.104 (0.035, 0.313)      \< 0.0001                   0.117 (0.037, 0.373)   \< 0.0001
  Previous treatment response                                                                                                                                                   
  Pre-treated                                133/142; 94%                                                                                                                       
  *vs* treatment-naive                       107/114; 94%                                          0.967 (0.349, 2.681)      0.948                       0.457                  

This analysis excluded patients co-treated with IFN, and patients with premature discontinuation ("per protocol analysis");

Number of patients who achieved SVR12 in category/total number in category. Univariate and multivariate models for prediction of SVR \[*n* = 256, modified intention-to-treat (mITT) analysis\] were used. This mITT analysis excluded patients, who were lost to follow-up (*n* = 4). Significant calculations (*P* \< 0.05). RVR: Rapid viral response (hepatitis C virus RNA negative at treatment week 4); LTx: Liver transplantation; SVR: Sustained virological response; NA: Not available.

![SVR12 rates with respect to GT (A), and diverse direct acting antiviracombinations (B, both modified intention-to-treat). This mITT analysis excluded patients, who were lost to follow-up (*n* = 4). Additionally, three GT1x patients and one GT 5 patient achieved SVR12. For further subgroup analyses according to baseline parameters see Table [2](#T2){ref-type="table"}. 3D: Dasabuvir, Ombitasvir, and Paritaprevir/r; GT: Genotype; GT1x: Genotype 1, no subtype differentiable; P: Pegylated Interferon; R: Ribavirin; SR: Sofosbuvir, Ribavirin; SS: Sofosbuvir, Simeprevir; SL: Sofosbuvir, Ledipasvir; SD: Sofosbuvir, Daclatasvir; SVR: Sustained virological response.](WJG-22-8050-g002){#F2}

Predictors of SVR12
-------------------

For evaluation of predictors of SVR12, see Table [2](#T2){ref-type="table"}. Presence of liver cirrhosis (*P* = 0.005), a platelet count \< 100/nL (*P* \< 0.0001), and a MELD score ≥ 10 (*P* \< 0.0001) at baseline were significant negative predictors of SVR12 in our study cohort (univariate analysis). Multivariate analysis identified a platelet count \< 100/nL (*P* = 0.031), and a MELD score ≥ 10 (*P* \< 0.0001) at baseline as independent predictors for achievement of a diminished SVR12 rate (see Table [2](#T2){ref-type="table"} for details).

With respect to GT, in a "per-protocol" subgroup analysis of GT1 and GT3 patients strictly treated with IFN-free protocols, GT3 patients had a significantly lower SVR12 rate than GT1 patients (*P* = 0.016, univariate analysis).

However, in our cohort, treatment experience, sex, age, baseline viral load, and early virological kinetics were found not to be significant as predictors of SVR12.

Virological failure
-------------------

Virological failure was a rare event. No primary non-response or virological breakthrough occurred in our cohort. In addition, only 12 of the 256 patients (4.7%, mITT) suffered from virological relapse during follow-up (see Table [3](#T3){ref-type="table"} for baseline characteristics, treatment details, and resistance analysis of respective patients). One patient (No. 9 in Table [3](#T3){ref-type="table"}) exhibiting a liver cirrhosis with Child-Turcotte-Pugh (CTP) stadium A suffered from relapse after SOF/PR. In this patient liver function deteriorated upon relapse to CTP stadium C, and therefore the patient had to be listed for liver transplantation (at a MELD score of 28). After having achieved an active listing status, treatment was initiated with SOF/DCV for 24 wk, leading to SVR12. During treatment, the liver function restored to CTP stadium A, and thus, the patient could be de-listed for liver transplantation again.

###### 

Characteristics of patients, who died during treatment, discontinued treatment prematurely, or suffered from virological relapse after end of treatment

                                                                               **Age (yr)**   **Sex**   **BL viral load, IU/mL**   **GT**   **LCi**      **BL MELD**   **Previous treatment**   **Current treatment**   **Treatment duration**   **Cause for premature discontinuation**   **Outcome**   **RAV NS3 protease**   **RAV NS5A**       **RAV NS5B polymerase**
  ---------------------------------------------------------------------------- -------------- --------- -------------------------- -------- ------------ ------------- ------------------------ ----------------------- ------------------------ ----------------------------------------- ------------- ---------------------- ------------------ -------------------------
  Patients, who died during treatment, or discontinued treatment prematurely                                                                                                                                                                                                                                                                       
  No. 1                                                                        63             male      1.41 Mio                   1b       Yes          12            PR                       SOF/SMV                 12                       Sepsis                                    death                                                   
  No. 2                                                                        66             male      1.69 Mio                   1b       Yes, HTx     14            \-                       SOF/LDV                 5                        Intracranial bleeding                     death                                                   
  No. 3                                                                        55             male      56200                      1b       Yes, LTx     24            TVR/PR                   SOF/SMV/R               14                       Re-LTx, sepsis                            death                                                   
  No. 4                                                                        49             male      157000                     1a       Yes,         14            PR                       SOF/LDV/R               8                        Right-heart failure                       death                                                   
  No. 5                                                                        79             female    5.85 Mio                   1b       Yes          6             TVR/PR                   SOF/SMV                 10                       Back-pain                                 SVR 24                                                  
  No. 6                                                                        55             male      396000                     1a       Yes, TIPSS   10            PR                       SOF/DCV                 16                       Hepatic encephalopathy                    SVR 24                                                  
  Patients with relapse after end of treatment                                                                                                                                                                                                                                                                                                     
  No. 7                                                                        54             male      10300                      1a       Yes          8             PR                       SOF/PR                  12                                                                               NA                     NA                 NA
  No. 8                                                                        63             male      321000                     1b       \-           6             \-                       SOF/PR                  12                                                                               NA                     NA                 NA
  No. 9                                                                        43             female    408000                     1a       Yes          8             \-                       SOF/PR                  12                                                                               NA                     NA                 NA
  No. 10                                                                       40             male      2.74 Mio                   1b       \-           6             PR                       SOF/PR                  12                                                                               NA                     NA                 NA
  No. 11                                                                       48             male      4.89 Mio                   3a       No, LTx      11            PR                       SOF/DCV/R               24                                                                               F43F/L                 A30K               \-
  No. 12                                                                       56             female    1.38 Mio                   3a       Yes          7             PR                       SOF/DCV                 24                                                                               \-                     Y93H               S282S/T
  No. 13                                                                       38             male      3.39 Mio                   1b       \-           6             \-                       SOF/DCV                 12                                                                               Q80K                   L31M, Y93H         \-
  No. 14                                                                       52             male      2.47 Mio                   3a       Yes          10            \-                       SOF/DCV/R               24                                                                               \-                     Y93H               \-
  No. 15                                                                       55             female    3.03 Mio                   1a       \-           6             TVR/PR                   SOF/DCV                 12                                                                               T54S, R155K            L31M/L             \-
  No. 16                                                                       49             male      8340                       3        Yes          6             \-                       SOF/LDV/R               24                                                                               \-                     A30S               \-
  No. 17                                                                       52             male      239000                     1b       Yes          6             \-                       SOF/LDV/R               12                                                                               T54S, V55I, Q80K       Q30E               \-
  No. 18                                                                       57             male      137 (on SOF/R)             1a       Yes, HCC     11            SOF/R                    SOF/DCV                 12                                                                               \-                     L31M, P58S, Y93C   \-

BL: Baseline; GT: Genotype; HCC: Hepatocellular carcinoma; LCi: Liver cirrhosis; MELD: Model of end stage liver disease; P: Pegylated Interferon; R: Ribavirin; SOF: Sofosbuvir; SMV: Simeprevir; LDV: Ledipasvir; DCV: Daclatasvir; TVR: Telaprevir; RAV: Resistance associated variant; HTx: Heart transplantation; LTx: Liver transplantation; TIPSS: Transjugular portosystemic stent shunt; NA: Not available.

For GT1, 8/194 patients (4%) suffered from virological relapse, for GT3 a rate of 3/41 (9%) was found. All GT3 patients with relapse had advanced liver disease (cirrhosis or post-liver transplantation), while the GT1 cohort of relapsers was more heterogeneous. This emphasizes the new paradigm of GT3 (with advanced liver disease) being one of the harder-to-treat GT in the era of DAA (possibly due to an unintended "misfit design" of DAA with respect to this distinct genotype). In the group of IFN-free treated patients, the difference in SVR12 rates between GT1 and 3 was significant (*P* = 0.016, univariate analysis; Table [2](#T2){ref-type="table"}).

In all patients with virological relapse after IFN-free DAA treatment resistance analysis was performed: Patients receiving a NS5A inhibitor always revealed NS5A-specific resistance associated variants (RAV) after relapse. Only one patient was detected with a NS5B-polymerase RAV (see Table [3](#T3){ref-type="table"} for details).

Premature discontinuation of treatment
--------------------------------------

Altogether, 6 out of 256 (2.3%) patients discontinued treatment prematurely (see Table [3](#T3){ref-type="table"} for baseline characteristics, treatment details, and outcome). Four of those patients died during or shortly after discontinuation of treatment: two patients developed sepsis, one patient died from right-sided heart failure, and one patient died from cerebral hemorrhage. All these patients suffered from decompensated liver disease at baseline, two of those additionally were on immunosuppression due to prior organ transplantation (liver, and heart, respectively). Notably, these numbers are much too small to calculate significant associations between the respective causes of death and the DAA-class which had been used for HCV treatment, but the mere fact that 4 of our patients died emphasizes the need for treatment of those patients in an experienced tertiary center. However, these patients would have never been treated at time of IFN-containing regimens.

One patient discontinued due to back-pain after 10 wk of treatment, without contacting our center; nevertheless, this patient was found later on of having achieved SVR 24. Another patient with HCV GT1a, liver cirrhosis, and a transjugular portosystemic shunt (TIPSS) was discontinued after 4 mo of treatment due to several episodes of hepatic encephalopathy. Nevertheless, this patient also achieved SVR 24.

Side effects
------------

One hundred and forty-seven/237 (62%) patients with data available for side effects reported side effects during treatment (depicted in detail in Table [4](#T4){ref-type="table"}). In general, side effects were mild in intensity, thus, just one patient discontinued treatment prematurely due to a self-reported intolerance (*i.e*., back-pain; Table [3](#T3){ref-type="table"}). Overall, fatigue, headache, bone pain or joint pain, and myalgia were the most frequently reported side effects. As expected, the rate of side effects was found to differ significantly between patients with IFN-containing regimens versus patients with IFN-free treatment.

###### 

Patient self-reported side effects during treatment, and for comparison of self-reported side effects of PEG-interferon containing regimen and interferon-free treatment Fisher's exact test was used

  **Side effects**            **Overall[1](#T4FN1){ref-type="table-fn"}**   **PEG-IFN co-treatment[2](#T4FN2){ref-type="table-fn"}**   **IFN-free treatment[3](#T4FN3){ref-type="table-fn"}**   ***P* value**                
  --------------------------- --------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------- --------------- ---- ------- -----------
  Fatigue                     93                                            39.2%                                                      26                                                       54.2%           67   35.4%   0.020
  Cephalgia                   52                                            21.9%                                                      9                                                        18.8%           43   22.8%   0.697
  Bone/joint pain/myalgia     38                                            16.0%                                                      12                                                       25.0%           26   13.8%   0.077
  Nausea/vomiting             38                                            16.0%                                                      14                                                       29.2%           24   12.7%   0.008
                                                                                                                                                                                                                             
  0.163                                                                                                                                                                                                                      
                                                                                                                                                                                                                             
  Insomnia                    28                                            11.8%                                                      16                                                       33.3%           12   6.3%    \< 0.0001
  Vertigo                     16                                            6.8%                                                       6                                                        12.5%           10   5.3%    0.102
  Flu-like symptoms           14                                            5.9%                                                       12                                                       25.0%           2    1.1%    \< 0.0001
  Abdominal discomfort/pain   17                                            7.2%                                                       3                                                        6.3%            15   7.9%    1.000
  Pruritus                    18                                            7.6%                                                       4                                                        8.3%            13   6.9%    0.755
  Diarrhea                    13                                            5.5%                                                       7                                                        14.6%           6    3.2%    0.006
  Any rash                    14                                            5.9%                                                       7                                                        14.6%           7    3.7%    0.010
  Anorexia                    9                                             3.8%                                                       4                                                        8.3%            5    2.6%    0.085
  Nervousness                 7                                             3.0%                                                       4                                                        8.3%            3    1.6%    0.033
  Depression/fear             5                                             2.1%                                                       2                                                        4.2%            3    1.6%    0.267
  Dyspnoea                    7                                             3.0%                                                       4                                                        8.3%            3    1.6%    0.030
  Concentration weakness      4                                             1.7%                                                       2                                                        4.2%            2    1.1%    0.183
  Visual changes              4                                             1.7%                                                       1                                                        2.1%            3    1.6%    1.000
  Loss of hair                4                                             1.7%                                                       1                                                        2.1%            3    1.6%    1.000
  Tachycardia/palpitations    2                                             0.8%                                                       2                                                        4.3%            0    0.0%    0.040
  Meteorism                   3                                             1.3%                                                       0                                                        0.0%            3    1.6%    1.000
  Aggression                  2                                             0.8%                                                       2                                                        4.2%            0    0.0%    0.040
  Fever/chills                1                                             0.4%                                                       1                                                        2.1%            0    0.0%    0.200
  Attacks of sweating         1                                             0.4%                                                       1                                                        2.1%            0    0.0%    0.200
  Gingivitis                  1                                             0.4%                                                       0                                                        0.0%            1    0.5%    1.000
  Cough                       1                                             0.4%                                                       1                                                        2.1%            0    0.0%    0.200
  Neurological symptoms       1                                             0.4%                                                       0                                                        0.0%            1    0.7%    1.000

Side effect reports were available in 237 of 260 patients;

In PEG-IFN co-treated patients (*n* = 51), side effect reports were available in 48 patients;

In IFN-free treated patients (*n* = 209), side effects reports were available in 189 patients. Significant calculations (*P* \< 0.05) are printed in bold. IFN: Interferon.

Hospital admissions were required during treatment with DAA-based regimens in 22 (8.6%) patients. Some of those patients had to be hospitalized twice or more. Reasons for hospitalization were: infections (*n* = 8; 4%), hepatic decompensation (*n* = 3; 1.5%), cardiovascular disease (*n* = 3), cholestatic hepatitis after liver transplantation (*n* = 2), treatment of hepatocellular carcinoma (*n* = 2), lumbago, vomitus, and diabetes insipidus, right upper quadrant pain (*n* = 1, each). Of those hospitalized, 4 patients deceased: Two patients died from infectious complications, and two patients died from cardiovascular disease (right-heart failure, intracerebral bleeding, respectively; see above, and Table [3](#T3){ref-type="table"} for details).

One hundred and ten patients received R as part of their combination treatment. Of those, 5 patients had to reduce R dosage due to anemia (4.5%), and 2 due to renal impairment. 2 patients had to completely withdraw R, one due to pruritus, and the other due to hemolysis, respectively.

DISCUSSION
==========

This "real-world" monocentric retrospective cohort study analyzing safety, efficacy, and predictors of SVR12 of second generation DAA treatment shows impressive overall SVR rates (93.7%).

Due to the relatively small number of patients and the retrospective character of this study a comparison between subgroups according to DAA combination partners is only of limited significance.

Furthermore, due to the lesser tolerability and presumed lower activity of SOF/PR in patients with advanced liver disease, this treatment *a priori* was reserved in our hands to patients showing up with a well-compensated liver function only.

The results in our heterogeneous cohort, containing meaningful fractions of hard-to-treat patients (liver cirrhosis, portal hypertension, post-liver transplantation) are similar to SVR rates of so far published study trials: our cohort of PR or R co-treated patients achieved a SVR rate of 93%, while in the NEUTRINO trial the cohort treated with SOF/PR achieved a SVR rate in previously untreated patients of 90%\[[@B19]\], and the VA-real world cohort achieved SVR12 in 66.8%-79%\[[@B20]\].

In other "real-world" analyses with SMV ± R as combination partners of SOF, SVR rates of 74.1%-84.2% were achieved\[[@B20]-[@B22]\]. In the OPTIMIST study, a phase III trial, a SVR12 rate of 97% in non-cirrhotic patients\[[@B23]\], while in the OPTIMIST-2 study treating cirrhotic patients with SOF, SMV ± R, SVR 12 in 83% of patients was achieved\[[@B24]\]. However, in our cohort, with more than half of patients being patients with liver cirrhosis, we achieved a SVR rate of 93% with this combination of drugs.

For patients with SOF, DCV ± R as combination partners, SVR rates of 86%-93% have been reported\[[@B25]\]. In our cohort, we were in line with those results and could achieve a SVR rate of 92%, including two patients with recurrent cholestatic Hepatitis C post-liver transplantation, one of those being a non-responder to a prior Telaprevir triple therapy being undertaken post-liver transplantation, and both decompensated at the beginning of treatment.

In previously treated and untreated patients with HCV, a combination of LDV ± R, and SOF led to SVR rates of 94%-99%\[[@B26]-[@B28]\], which is in line with results of our cohort, in which we could register a SVR12 rate of 94%, while in another real-world analysis, SVR rates of 91.3%-92% were achieved\[[@B29]\].

For our small group of 3D regimen-receiving patients, we could achieve SVR in 100%, while in the Phase III trials SVR rates of 91.8%-99.5% were observed\[[@B30],[@B31]\].

Thus, altogether, favorable SVR rates achieved in the randomized controlled clinical trials could be translated into the "real-world", and importantly, in our cohort; even extra hard-to-treat groups of patients exhibited favorable treatment outcomes (SVR12 post-liver transplantation: 88%, SVR12 in cirrhotic patients with platelets \< 100/nL: 82%), which exceed results with former treatment options by far\[[@B15],[@B32]\].

Nevertheless, patients with liver cirrhosis show significantly lower response rates (87% with liver cirrhosis, 97% without; *P* = 0.005), and especially those with advanced portal hypertension (platelets \< 100/nL), or high MELD score (≥ 10) show significantly lower SVR12 rates than patients without (*P* \< 0.0001, uni- and multivariate analysis). These findings were also observed in other real world studies with low platelets, low albumin and liver cirrhosis as negative predictors of SVR in larger cohorts\[[@B21],[@B33],[@B34]\]. Thus, this subgroup of patients still resembles a group of patients in the "catch 22"-situation of being in the greatest need of treatment while showing the lowest response rates. Moreover, the whole drug class of HCV protease inhibitors (represented by SMV, and Paritaprevir/r) is not recommendeded for those patients (CTP B "plus") due to hepatotoxicity. Therefore, new strategies are needed to tackle this problem, *e.g*., by implementation of screening programs to identify patients infected with HCV at an early stage of their liver disease, and more importantly by development of more potent agents in the near future. However, 4 patients were lost in our cohort. Even if not associated with anti-HCV medication, this emphasizes, that treatment of patients with advanced liver disease should remain in the hands of experienced tertiary centers even in times of "easy" treatment with second generation DAA.

In our cohort, results of early viral kinetics had no impact on prediction of SVR12, thus costly "in-between" measurements of HCV viral load possibly are expendable.

Previous treatment with PR may not play a role any more in treatment decisions, as in our cohort previous treatment was not identified as a negative predictor of SVR, as it was in the HCV-TARGET cohort\[[@B21]\].

Most probably due to the favorable tolerability and low-toxicity profile of second generation DAA, and the omission of pegylated Interferon, now also senior patients benefit from SOF-based DAA treatment on the same scale as younger patients do\[[@B21]\].

Another subgroup of patients in need of further research efforts seems to be the one with GT3: Even though we could achieve a favorable overall SVR rate of 90%, at least in IFN-free treatment regimens, the SVR rates in a "per-protocol" analysis are significantly lower in GT3 patients than in GT1 (80% in GT3, 98% in GT1, respectively, *P* = 0.016; univariate analysis), again with a special negative focus on patients with GT3 and concomitant advanced liver disease. Moreover, means are limited with respect to treatment of GT3 due to the insufficient antiviral activity of protease- and NS5A-inhibitors (except DCV) in this GT. However, new pangenotypic NS5A inhibitors like Velpatasvir or upcoming new pangenotypic protease inhibitors hopefully close that gap in the near future.

However, since DAA treatment forms RAVs in the viriom of patients, pretreatment with DAA of any generation has to be considered more and more in future treatment attempts after any prior exposure to DAA. All patients in our cohort, who suffered from virological relapse showed RAVs at time-point of relapse. Especially NS5A-RAVs are frequent due to the low resistance barrier of NS5A-inhibitors, as exemplified also in our "real-word" cohort. Since NS5A-RAVs lead to just minimal impairment of viral "fitness", unfortunately they are detectable for a long time in exposed patients\[[@B35]\]. While for some RAVs (like NS5A L31M, Y93H) clear associations between existence of RAV and virological failure exist, for others (like NS5A A30S) this association is not well established\[[@B35]\]. This may lead to confusion in case of a future re-treatment, if minor RAVs have been detected, and even more in case of a baseline test in treatment naïve patients. However, as the population of patients with relapse after DAA treatment grows, the need for controlled trials with new DAA-combinations (*e.g*., pangenotypic protease inhibitor) for those patients to address this problem is obvious. Therefore, after virological relapse we recommend resistance testing for individualized adjustment of future DAA therapies.

In our retrospective analysis excellent SVR12 rates of second generation DAA could be translated from the large study trials into "real-world" scenarios. Patients with advanced liver disease, signs of portal hypertension, especially with platelets \< 100/nL, or MELD ≥ 10, and patients with GT3 are at relatively higher risk to suffer from virological failure and development of resistance associated variants after exposure to DAA. To overcome this unsolved problem, further research efforts are needed.

COMMENTS
========

Background
----------

From 2014 on, successively the second wave of direct acting antiviral agents (Sofosbuvir, Daclatasvir, Simeprevir, Ledipasvir, Dasabuvir, Ombitasvir, Paritaprevir/r) was available for treatment of chronic hepatitis C infection. In randomized clinical trials, superb rates of sustained virological response (SVR) 12 could be achieved.

Research frontiers
------------------

Due to the more heterogeneous character of patients in the "real world", the therapeutic performance of these new drugs outside randomized clinical trials is of interest. Therefore, in this monocentric retrospective cohort study, we analyzed the efficacy, safety, and predictors of SVR 12 for treatment with combinations of second generation direct acting antivirals in a "real-world" setting.

Innovations and breakthroughs
-----------------------------

In this retrospective study, similar SVR rates could be achieved compared to randomized clinical trials. However, certain subgroups of patients have significantly lower viral response rates: Significant negative predictors of SVR12 were a platelet count \< 100/nL, a MELD score ≥ 10 (both *P* \< 0.0001), liver cirrhosis at baseline (*P* = 0.005). Moreover, in Interferon-free treatment patients with HCV genotype 3 had significantly lower SVR rates than patients with HCV genotype 1 (*P* = 0.016). In the future, these subgroups of patients should be more in the focus of research efforts to overcome lower rates of SVR.

Applications
------------

Current retrospective analysis shows that excellent SVR12 rates and the favorable side-effect profile of direct acting antiviral-combination therapy can be well translated into "real-world".
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